See more : Inscape Corporation (ICPBF) Income Statement Analysis – Financial Results
Complete financial analysis of Altimmune, Inc. (ALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Altimmune, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kobelco Wire Company, Ltd. (5660.T) Income Statement Analysis – Financial Results
- Xanadu Mines Limited (XANAF) Income Statement Analysis – Financial Results
- Leo Global Logistics Public Company Limited (LEO.BK) Income Statement Analysis – Financial Results
- Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) Income Statement Analysis – Financial Results
- Microba Life Sciences Limited (MAP.AX) Income Statement Analysis – Financial Results
Altimmune, Inc. (ALT)
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 426.00K | -68.00K | 4.41M | 8.19M | 5.80M | 10.33M | 41.50K | 5.23M | 10.64M | 10.19M | 17.91M | 25.18M | 24.27M | 20.99M | 27.55M | 32.91M | 14.64M | 1.85M | 586.07K |
| Cost of Revenue | 477.00K | 68.00K | 551.30K | 33.51M | 17.07M | 18.46M | 18.41M | 7.22M | 5.06M | 4.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 115.00K |
| Gross Profit | -51.00K | -136.00K | 3.86M | -25.32M | -11.26M | -8.13M | -18.36M | -1.99M | 5.58M | 5.93M | 17.91M | 25.18M | 24.27M | 20.99M | 27.55M | 32.91M | 14.64M | 1.85M | 471.07K |
| Gross Profit Ratio | -11.97% | 200.00% | 87.50% | -309.40% | -194.16% | -78.68% | -44,249.39% | -38.07% | 52.41% | 58.15% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 80.38% |
| Research & Development | 65.80M | 70.54M | 74.54M | 49.77M | 17.77M | 18.46M | 18.41M | 4.84M | 5.13M | 9.32M | 15.29M | 19.51M | 21.22M | 20.88M | 30.22M | 31.81M | 16.56M | 0.00 | 0.00 |
| General & Administrative | 18.14M | 17.13M | 15.41M | 13.21M | 8.50M | 9.77M | 8.46M | 11.52M | 6.22M | 10.91M | 13.28M | 11.63M | 14.31M | 18.02M | 22.43M | 19.40M | 13.88M | 491.09K | 145.78K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.14M | 17.13M | 15.41M | 13.21M | 8.50M | 9.77M | 8.46M | 11.52M | 6.22M | 10.91M | 13.28M | 11.63M | 14.31M | 18.02M | 22.43M | 19.40M | 13.88M | 491.09K | 145.78K |
| Other Expenses | 12.42M | -32.00K | -373.87K | 24.15K | 15.14K | 277.89K | 5.67K | 7.85K | 8.14K | -762.00 | -6.07K | 47.86K | 461.07K | 5.66M | 872.30K | 813.89K | 705.37K | 153.29K | 0.00 |
| Operating Expenses | 96.36M | 87.67M | 89.95M | 62.98M | 26.27M | 28.22M | 16.17M | 16.49M | 11.50M | 20.38M | 28.75M | 31.44M | 35.99M | 44.55M | 53.52M | 52.02M | 31.15M | 644.38K | 145.78K |
| Cost & Expenses | 96.36M | 87.67M | 89.95M | 62.98M | 26.27M | 28.22M | 16.17M | 16.49M | 11.50M | 20.38M | 28.75M | 31.44M | 35.99M | 44.55M | 53.52M | 52.02M | 31.15M | 644.38K | 260.78K |
| Interest Income | 7.35M | 2.87M | 202.74K | 322.51K | 843.41K | 226.60K | 47.58K | 1.05K | 0.00 | 695.00M | 2.58K | 17.81K | 16.66K | 6.96K | 269.13K | 1.23M | 1.12M | 1.85M | 586.07K |
| Interest Expense | 35.00K | 8.00K | 5.66K | 9.42K | 2.24K | 297.09K | 162.14K | 168.15B | 54.58K | 210.40K | 369.28K | 342.56K | 54.57K | 5.94M | 2.84M | 2.57M | 2.12M | 0.00 | 0.00 |
| Depreciation & Amortization | 477.00K | 500.00K | 551.30K | 298.06K | 387.32K | 302.37K | 139.02K | 135.35K | 141.60K | 149.96K | 182.49K | 303.92K | 461.07K | 1.02M | 872.30K | 813.89K | 655.21K | 0.00 | 0.00 |
| EBITDA | -87.94M | -84.40M | -96.53M | -54.15M | -20.19M | -44.72M | -51.76M | -10.91M | -3.18M | -9.53M | -11.10M | -4.08M | -3.28M | -23.26M | -28.57M | -33.03M | -15.80M | -14.05M | 325.30K |
| EBITDA Ratio | -20,642.02% | 124,855.88% | -1,943.50% | -661.62% | -331.28% | -165.39% | -38,725.67% | -4,344.78% | 16.47% | -98.55% | -59.48% | -23.42% | -79.25% | -59.69% | -77.55% | -7.12% | -134.63% | 65.13% | 55.50% |
| Operating Income | -95.93M | -87.74M | -96.91M | -54.80M | -21.46M | -42.83M | -52.05M | -11.26M | -3.40M | -10.19M | -10.84M | -6.27M | -11.73M | -23.55M | -25.97M | -35.24M | -16.50M | 1.20M | 325.30K |
| Operating Income Ratio | -22,518.54% | 129,029.41% | -2,197.42% | -669.50% | -370.00% | -414.61% | -125,401.20% | -215.37% | -31.98% | -100.01% | -60.51% | -24.89% | -48.32% | -112.19% | -94.28% | -107.09% | -112.70% | 65.13% | 55.50% |
| Total Other Income/Expenses | 7.48M | 2.83M | -176.82K | 337.24K | 886.30K | -2.49M | -18.51K | 4.85K | 3.21M | 297.66K | -4.62M | -758.20K | 7.93M | -11.30M | -6.31M | -1.17M | 2.92M | 15.74M | 0.00 |
| Income Before Tax | -88.45M | -84.91M | -97.09M | -54.46M | -20.58M | -45.32M | -52.06M | 205.02M | -3.38M | -9.89M | -11.66M | -4.72M | -3,797.57B | -34,849.28B | -32.28B | -36.42B | -13.59M | 1.20M | 325.30K |
| Income Before Tax Ratio | -20,762.21% | 124,867.65% | -2,201.43% | -665.38% | -354.72% | -438.68% | -125,445.79% | 3,920.00% | -31.76% | -97.09% | -65.07% | -18.77% | -15,649,592.52% | -165,999,488.89% | -117,168.01% | -110,646.14% | -92.79% | 65.13% | 55.50% |
| Income Tax Expense | 0.00 | -197.00K | -919.51K | -5.42M | -58.50K | -6.15M | -5.64M | 11.17M | 61.75K | 61.75K | 61.75K | 195.53K | -7.93M | 15.93M | 6.31M | 17.30M | -2.87M | 187.00K | 48.00K |
| Net Income | -88.45M | -84.71M | -96.17M | -49.04M | -20.52M | -39.17M | -46.43M | 193.85M | -3.44M | -9.96M | -11.72M | -4.92M | -3.80M | -34.85M | -32.28M | -36.42M | -13.59M | 1.02M | 277.30K |
| Net Income Ratio | -20,762.21% | 124,577.94% | -2,180.58% | -599.20% | -353.71% | -379.16% | -111,860.32% | 3,706.44% | -32.34% | -97.70% | -65.42% | -19.54% | -15.65% | -166.00% | -117.17% | -110.65% | -92.79% | 55.01% | 47.31% |
| EPS | -1.66 | -1.81 | -2.33 | -1.91 | -1.56 | -13.98 | -108.77 | -49.80 | -16.13 | -51.91 | -69.40 | -30.55 | -24.07 | -323.59 | -351.19 | -476.15 | -431.69 | -11.48K | 12.00 |
| EPS Diluted | -1.66 | -1.81 | -2.33 | -1.91 | -1.56 | -13.98 | -108.77 | -49.80 | -16.13 | -51.91 | -69.40 | -30.55 | -24.07 | -323.59 | -351.19 | -476.15 | -431.69 | -11.48K | 9.00 |
| Weighted Avg Shares Out | 53.25M | 46.93M | 41.28M | 25.64M | 13.12M | 2.80M | 426.83K | 230.38K | 213.28K | 191.78K | 168.86K | 161.08K | 157.77K | 107.70K | 91.92K | 76.48K | 31.48K | 1.89K | 26.23K |
| Weighted Avg Shares Out (Dil) | 53.25M | 46.93M | 41.28M | 25.64M | 13.12M | 2.80M | 426.83K | 230.38K | 213.28K | 191.78K | 168.86K | 161.08K | 157.77K | 107.70K | 91.92K | 76.48K | 31.48K | 1.89K | 27.74K |
July 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - ALT
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
The Gross Law Firm Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024 – ALT
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Levi & Korsinsky Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
NEW YORK , July 1, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune...
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Source: https://incomestatements.info
Category: Stock Reports